Use of metoprolol as a relevant therapeutic agent in patients with cardiovascular disorders: A review
Abstract
This chapter has gathered scientific evidence on metoprolol as a pharmacological tool in various cardiovascular diseases. METHODOLOGY: This is a systematic review in which scientific articles published in Pubmed databases between 2021 and 2022 were selected. The following descriptors were used: metoprolol or pharmacokinetic, pharmacodynamics, efficacy, adverse effect, combined by means of the AND operator. A total of 46 articles were found, of which 17 met the selection criteria and, therefore, are included in this study. RESULTS: Regarding the clinical use of metoprolol, it was beneficial in the treatment of arrhythmias after resection of hepatocarcinoma, in cardiac improvement in patients with permanent pacemaker, in individuals with obstructive hypertrophic cardiomyopathy, and in addition to having been cited in the increase in survival in patients with type B aortic dissection. has been shown to be beneficial in both heart failure and carotid atherosclerosis, as well as hypothalamic obesity. With regard to adverse events, patients on metoprolol were more prone to nightmares than those exposed to another beta-adrenergic antagonist drug, such as carvedilol or labetalol. In addition, when compared with another drug, it did not have an advantage over esmolol for performing CT angiography and was less effective in antihypertensive therapy of men with erectile dysfunction. Finally, with regard to new methods of detection or therapeutic intervention of the use of metoprolol, one study was successful in discovering a new way to quantify metoprolol in rat plasma, while another recent study addressed relevant considerations in personalized therapy of the drug, based on the genetic polymorphism of CYP2D6. CONCLUSION: The present systematic review corroborates updates on the use of Metoprolol found in the current literature, contributing to the institution of personalized therapy for patients with cardiovascular disease.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2023 Rachel Melo Ribeiro, Gildean Pereira Costa, Isabela Carolyne de Melo Costa, Marina Gomes Cantanhede, João Pedro Lima dos Santos, Wesley do Nascimento Silva, Emanoel Ribeiro de Brito Junior, João Pedro Silva Majewski, Jhonata Costa Moura, Ellen Caroline da Silva PenhaAuthor(s)
-
Rachel Melo Ribeiro
-
Gildean Pereira Costa
-
Isabela Carolyne de Melo Costa
-
Marina Gomes Cantanhede
-
João Pedro Lima dos Santos
-
Wesley do Nascimento Silva
-
Emanoel Ribeiro de Brito Junior
-
João Pedro Silva Majewski
-
Jhonata Costa Moura
-
Ellen Caroline da Silva Penha